Publications by authors named "R L C Starling"
Objectives: To identify possible etiology-specific differences in preoperative risk factors for major adverse events during Impella 5.5 support in patients with ischemic (ICM) and nonischemic cardiomyopathy (NICM).
Methods: From October 2019 to January 2023, 228 Impella 5.
Background: The win ratio (WR) is an emerging alternative for reporting composite outcomes, prioritizing clinically significant events such as mortality while incorporating surrogate measures. However, its benefits should be weighed against limitations, particularly the influence of lower hierarchical outcomes. This secondary analysis of the PARAGLIDE-HF trial performed a WR sensitivity analysis using a modified hierarchical composite outcome to assess the utility of WR sensitivity analysis and the efficacy of sacubitril/valsartan versus valsartan.
View Article and Find Full Text PDFDeveloping a smartphone web app to help DWI offenders and their families.
J Subst Use Addict Treat
January 2025
Article Synopsis
- The study focused on developing a smartphone-web app aimed at supporting DWI offenders and their concerned family members (CFMs) during and after the use of ignition interlock devices (IIDs).
- Key findings from interviews and focus groups revealed that both DWI offenders and CFMs face challenges such as a lack of information, financial strain, and the importance of supportive communication, leading to the creation of four app modules.
- Usability testing showed that the app was user-friendly and met the needs of its target audience, highlighting the need for further research to assess its effectiveness.
Background: Impella 5.5 is a temporary left ventricular assist device utilized to support patients with cardiogenic shock and those undergoing high-risk cardiac interventions.
Methods: From October 2019 to January 2023, 226 patients received Impella 5.
Article Synopsis
- Novel transcatheter therapies for tricuspid regurgitation (TR) show promise, but their suitability for the general TR patient population is still uncertain.
- In a study involving 178 patients with moderate symptomatic TR, only 10.7% qualified for investigative therapies, while many received off-label clipping, surgery, or medical treatment due to factors like unsuitable anatomy or existing health issues.
- Although the investigative group experienced significant improvement in TR severity after one year compared to the medical treatment group, their outcomes were similar to off-label clipping but not as favorable as surgery, highlighting the need for broader access to effective therapies for TR patients.